Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery
oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]
AI Summary: Eikon Therapeutics successfully raised $381 million in its IPO, reinforcing investor confidence in novel biotechnology approaches for cancer drug discovery. The fundraising milestone is expected to accelerate live‐cell imaging and other innovative oncology research initiatives.
Related Stories
Therapeutic HPV vaccine slows throat tumors in preclinical tests / 4 months
Gene‑editing trials explore one‑time fix for high cholesterol / 4 months
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 5 months
Aktis Oncology IPO boosts radiopharmaceutical pipeline / 6 months
Tumor bacteria drive head and neck immunotherapy resistance / 6 months
Giredestrant lowers recurrence risk in early-stage breast cancer / 7 months
Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 7 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Olfaction, Supply Chain, Reproductive Health and look for the RSS link.
StackHealth Time Machine